Search Results - "Pedersen, Karen Boje"

Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study by Rasmussen, Jon Jarløv, Selmer, Christian, Østergren, Peter Busch, Pedersen, Karen Boje, Schou, Morten, Gustafsson, Finn, Faber, Jens, Juul, Anders, Kistorp, Caroline

“…Abuse of anabolic androgenic steroids (AAS) is highly prevalent among male recreational athletes. The objective of this study was to investigate the impact of…”
Get full text

Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial by Pratley, Richard, Amod, Aslam, Hoff, Søren Tetens, Kadowaki, Takashi, Lingvay, Ildiko, Nauck, Michael, Pedersen, Karen Boje, Saugstrup, Trine, Meier, Juris J

“…Glucagon-like peptide-1 (GLP-1) receptor agonists are effective treatments for type 2 diabetes, lowering glycated haemoglobin (HbA1c) and weight, but are…”
Get full text

956-P: Efficacy and Safety of Oral Semaglutide When Added to Basal, Premix, or Basal-Bolus Insulin by MOSENZON, OFRI, ARODA, VANITA R., CHRISTIANSEN, ERIK, HARRIS, STEWART B., PEDERSEN, KAREN BOJE, TARP-JOHANSEN, MADS JEPPE, ZINMAN, BERNARD

“…An exploratory subgroup analysis of the 52-week, double-blind PIONEER 8 trial (NCT03021187) evaluated the effect of background insulin regimen (basal,…”
Get full text

985-P: Oral Semaglutide as Add-On to Insulin in T2D: PIONEER 8 by ZINMAN, BERNARD, ARODA, VANITA R., BUSE, JOHN B., CARIOU, BERTRAND, HARRIS, STEWART B., HOFF, SOREN T., PEDERSEN, KAREN BOJE, TARP-JOHANSEN, MADS JEPPE, ARAKI, EIICHI

“…Patients (pts) with T2D uncontrolled on insulin ± metformin were randomized to oral semaglutide (sema) 3 mg (N=184), 7 mg (N=182) or 14 mg (N=181), or placebo…”
Get full text

55-OR: Oral Semaglutide vs. Liraglutide and Placebo in T2D: PIONEER 4 by PRATLEY, RICHARD E., AMOD, ASLAM, HOFF, SOREN T., KADOWAKI, TAKASHI, LINGVAY, ILDIKO, NAUCK, MICHAEL A., PEDERSEN, KAREN BOJE, SAUGSTRUP, TRINE, MEIER, JURIS J.

“…Patients (pts) with T2D uncontrolled on metformin ± SGLT2i were randomized to oral semaglutide (sema) 14 mg once daily (N=285), liraglutide (lira) 1.8 mg…”
Get full text